US5422352A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Slimming pharmaceutical composition
Assignee: Takeda Pharma AS
•
Filing: 1992-12-21
•
Granted: 1995-06-06
•
Expires: 2012-12-21
Abstract
Abstract The present invention is directed to a method for reducing the weight of a human and a method for reducing the adipose tissue mass/lean mass body mass ratio of a human or a domestic animal. In each method, an effective dose of a combination of ephedrine and caffeine are administered in a weight ratio of about 1:12, respectively, calculated on the amount of ephedrine in the form of the free base.
Inventors
- 👤 Arne Astrup
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 19:35
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/475; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61P; A61P3/00; A61P3/04
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
76 words
A method for reducing the weight of a human, comprising: administering to the human a thermogenically effective dose of an ephedrine and caffeine in a weight ratio of about 1:12, calculated on the amount of ephedrine in the form of the free base, said dose being administered either as a single dose comprising a combination of ephedrine and caffeine or as separate doses administered substantially concomitantly and each dose containing one of ephedrine and caffeine, respectively.
Claim 2
Independent Claim
76 words
A method for reducing the weight of a human, comprising: administering to the human a thermogenically effective dose of an ephedrine and caffeine in a weight ratio of about 1:12, calculated on the amount of ephedrine in the form of the free base, said dose being administered either as a single dose comprising a combination of ephedrine and caffeine or as separate doses administered substantially concomitantly and each dose containing one of ephedrine and caffeine, respectively.
Claim 3
Dependent Claim
39 words
A method according to claim 1, wherein the ephedrine is at least one of a L-ephedrine selected from the group consisting of (1R, 2S)-2-methyl-amino-1-phenyl-1-propanol or a pharmaceutically acceptable salt thereof and (1S, 2R)-2-methylamino-1-phenyl-1-propanol or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
22 words
A method according to claim 1, wherein the caffeine is in the form of a pharmaceutically acceptable salt or a complex thereof.
Claim 5
Dependent Claim
32 words
A method according to claim 1, wherein the amount of the ephedrine is about 10-40 mg per unit dose, calculated on the amount of ephedrine in the form of the free base.
Claim 6
Dependent Claim
32 words
A method according to claim 1, wherein the amount of the ephedrine is about 16-17 mg per unit dose, calculated on the amount of ephedrine in the form of the free base.
Claim 7
Independent Claim
82 words
A method for reducing the adipose tissue mass/lean mass body mass ratio of a human, comprising: administering to the human a thermogenically effective dose of an ephedrine and caffeine in a weight ratio of about 1:12, calculated on the amount of ephedrine in the form of the free base, said dose being administered either as a single dose comprising a combination of ephedrine and caffeine or as separate doses administered substantially concomitantly and each dose containing one of ephedrine and caffeine, respectively.
Claim 8
Independent Claim
82 words
A method for reducing the adipose tissue mass/lean mass body mass ratio of a human, comprising: administering to the human a thermogenically effective dose of an ephedrine and caffeine in a weight ratio of about 1:12, calculated on the amount of ephedrine in the form of the free base, said dose being administered either as a single dose comprising a combination of ephedrine and caffeine or as separate doses administered substantially concomitantly and each dose containing one of ephedrine and caffeine, respectively.
Claim 9
Dependent Claim
39 words
A method according to claim 6, wherein the ephedrine is at least one of a L-ephedrine selected from the group consisting of (1R, 2S)-2-methyl-amino-1-phenyl-1-propanol or a pharmaceutically acceptable salt thereof and (1S, 2R)-2-methylamino-1-phenyl-1-propanol or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
22 words
A method according to claim 6, wherein the caffeine is in the form of a pharmaceutically acceptable salt or a complex thereof.
Claim 11
Dependent Claim
32 words
A method according to claim 6, wherein the amount of the ephedrine is about 10-40 mg per unit dose, calculated on the amount of ephedrine in the form of the free base.
Claim 12
Dependent Claim
32 words
A method according to claim 6, wherein the amount of the ephedrine is about 16-17 mg per unit dose, calculated on the amount of ephedrine in the form of the free base.
Claim 13
Independent Claim
52 words
A method for reducing the fat tissue mass/lean mass body mass ratio of a domestic animal, comprising: administering to the animal an effective dose of a combination of an ephedrine and caffeine in a weight ratio of about 1:12, calculated on the amount of ephedrine in the form of the free base.
Claim 14
Independent Claim
52 words
A method for reducing the fat tissue mass/lean mass body mass ratio of a domestic animal, comprising: administering to the animal an effective dose of a combination of an ephedrine and caffeine in a weight ratio of about 1:12, calculated on the amount of ephedrine in the form of the free base.
Claim 15
Dependent Claim
39 words
A method according to claim 11, wherein the ephedrine is at least one of a L-ephedrine selected from the group consisting of (1R, 2S)-2-methyl-amino-1-phenyl-1-propanol or a pharmaceutically acceptable salt thereof and (1S, 2R)-2-methylamino-1-phenyl-1-propanol or a pharmaceutically acceptable salt thereof.
Claim 16
Dependent Claim
22 words
A method according to claim 11, wherein the caffeine is in the form of a pharmaceutically acceptable salt or a complex thereof.
Claim 17
Dependent Claim
21 words
A method according to claim 11, wherein the domestic animal is selected from the group consisting of cattle, pigs and sheep.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-06-05 | 1998-12-05 | 1999-06-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-06-05 | 2002-12-05 | 2003-06-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-06-05 | 2006-12-05 | 2007-06-06 | $7700.00 | Window Closed / Lapsed |